EUCTR2008-006124-64-IT进行中（未招募）不适用
A phase IIIb, open-label, randomised, multicentre study to evaluate the immunogenicity and safety of a booster dose of GlaxoSmithKline Biologicals? dTpa-IPV vaccine (Boostrix Polio) compared with Sanofi-Pasteur-MSD?s DTPa-IPV (Tetravac), when co-administered with MMRV (Priorix Tetra) in 5 to 6-year-old healthy children. - dTpa-IPV-010
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •A male or female child of 5 and 6 years of age (up to, but excluding 7 years of age) at the time of vaccination. - Subjects who received a complete 3-dose vaccination with a DTPa-based combined vaccine according to a 3-5-11 month schedule in line with recommendations in Italy. The first two vaccine doses must have been administered before 9 months of age, the third dose must have been received between 10 and 18 months of age, and there must have been at least one month between each vaccination. - Subjects who received a first dose of a live attenuated measles-mumps-rubella vaccine in the second year of life, in line with recommendations in Italy. - Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol (e.g. completion of the diary cards, return for follow-up visits) should be enrolled in the study. - Written informed consent obtained from the parent or guardian of the subject. - Healthy subjects as established by medical history and clinical examination before entering into the study
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. - Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the booster vaccine dose. For corticosteroids, this will mean prednisone ≥ 0.5 mg/kg/day, or equivalent Inhaled and topical steroids are allowed. - Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period. - Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device). - Previous booster vaccination against tetanus, diphtheria, pertussis and/or poliomyelitis since vaccination in the first two years of life. - Previous measles, mumps, rubella and/or varicella second dose vaccination. - Known history of diphtheria, tetanus, pertussis, poliomyelitis, measles, mumps, rubella and/or varicella disease. - Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to study start. - Any confirmed or suspected immunosuppressive or immunodeficiency condition, based on medical history and physical examination (no laboratory testing required). - History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. - Administration of immunoglobulin and/or any blood products within the three months preceding vaccination or planned administration during the study period. - Occurrence of transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus. - Occurrence of any of the following adverse events (AEs) after a previous administration of a DTP vaccine: Hypersensitivity reaction to any component of the vaccine; Encephalopathy of unknown aetiology occurring within 7 days following previous vaccination with pertussis-containing vaccine; Fever ≥ 40C (axillary temperature/oral temperature) within 48 hours of vaccination, not due to another identifiable cause; Collapse or shock-like state (hypotonic-hyporesponsiveness episode) within 48 hours of vaccination; Convulsions with or without fever, occurring within 3 days of vaccination. - Residence in the same household as a high risk person for varicella e.g.: Newborn infant (0-4 weeks of age) Pregnant women who have a negative history for chickenpox Persons with known immunodeficiency - The following condition is temporary or self-limiting, and a subject may be vaccinated once the condition has resolved if no other exclusion criteria is met: Current febrile illness or axillary temperature ≥ 38.5 ºC or other moderate to severe illness within 24 hours of study vaccine administration
研究者
相似试验
进行中（未招募）
不适用
Evaluation of immunogenicity and safety of two 2-dose Human Papillomavirus (HPV) vaccine schedules in 9-14 year old girls.EUCTR2011-000757-22-DEGlaxoSmithKline Biologicals1,428
进行中（未招募）
不适用
Evaluation of immunogenicity and safety of two 2-dose Human Papillomavirusthe (HPV) vaccine schedules in 9-14 years old girls.EUCTR2011-000757-22-ITGLAXO SMITHKLINE1,428
进行中（未招募）
1 期
Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older.Healthy volunteers (Prevention of Herpes Zoster (HZ) and related complications in adults =50 years of age (YOA))MedDRA version: 20.0Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsEUCTR2017-001220-22-EEGlaxoSmithKline Biologicals912
进行中（未招募）
1 期
Immunogenicity and safety study of GSK Biologicals’ Herpes Zoster vaccine GSK1437173A when co-administered with Prevenar13 in adults aged 50 years and older.EUCTR2017-001220-22-DEGlaxoSmithKline Biologicals912
进行中（未招募）
不适用
An open-label, randomized, phase IIIB, multicenter trial to evaluate the pharmacodynamic parameters of intubation bolus, and bolus and infusion maintenance doses of Zemuron® in pediatric and adolescent subjectsot applicableEUCTR2005-002926-67-DEV Organon120